Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma

Trial Profile

Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2014

At a glance

  • Drugs Ramucirumab (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 14 Jul 2012 Additional trial location (United Kingdom) identified as reported by European Clinical Trials Database.
    • 14 Jul 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-006713-16).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top